Mark H. O'Hara, MD

faculty photo
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-306
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: (215)360-0735
Fax: (215)662-4646
Education:
BS (Biology - Molecular Genetics)
University of Rochester, 2004.
MD (Medicine)
Stony Brook School of Medicine, 2008.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

GI cancers, Phase 1 trials, Pancreatic cancer, Colorectal cancer, Anal cancer, Esophageal cancer, Gastric cancer, Hepatocellular carcinoma, Cholangiocarcinoma, Neuroendocrine tumor

Description of Research Expertise

Pancreatic cancer, colorectal cancer, GI cancers, Phase 1, CAR T cell therapy

Selected Publications

Till JE, Black TA, Gentile C, Abdalla A, Wang Z, Sangha HK, Roth JJ, Sussman R, Yee SS, O'Hara MH, Thompson JC, Aggarwal C, Hwang WT, Elenitoba-Johnson KS, Carpenter EL: Optimization of Sources of Circulating Cell-Free DNA Variability for Downstream Molecular Analysis. Journal of Molecular Diagnostics 23(11): 1545-1552, November 2021.

Gimotty PA, Till JE, Udgata S, Takenaka N, Yee SS, LaRiviere MJ, O'Hara MH, Reiss KA, O'Dwyer P, Katona BW, Herman D, Carpenter EL, Zaret KS: THSB2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma. Oncotarget 12(22): 2266-2272, October 2021.

Arscott WT, Nead KT, Bear A, Venigalla S, Shabason J, Lukens JN, Plastaras JP, Wojcieszynski A, Metz J, O'Hara M, Reiss KA, Teitelbaum U, Loaiza-Bonilla A, Drebin J, Lee 4th MK, Shroff SG, Ben-Josef E: Concurrent Nab-paclitaxel and Radiotherapy: Novel Radiosensitization for Borderline Resectable or Unresectable Pancreatic Cancer. American Journal of Clinical Oncology 44(9): 469-474, September 2021.

Byrne KT, Betts CB, Mick R, Sivagnanam S, Bajor DL, Laheru DA, Chiorean EG, O'Hara MH, Liudahl SM, Newcomb C, Alanio C, Ferreira AP, Park BS, Ohtani T, Huffman AP, Vayrynen SA, Dias Costa A, Kaiser JC, Lacroix AM, Redlinger C, Stern M, Nowak JA, Wherry EJ, Cheever MA, Wolpin BM, Furth EE, Jaffee EM, Coussens LM, Vonderheide RH: Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Clinical Cancer Research 27(16): 4574 - 4586, August 2021.

Bear AS, Blanchared T, Cesare J, Ford MJ, Richman LP, Xu C, Baroja ML, McCuaig S, Costeas C, Gabunia K, Scholler J, Posey Jr AD, O'Hara MH, Smole A, Powell Jr DJ, Garcia BA, Vonderheide RH, Linette GP, Carreno BM: Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting. Nature Communications 12(1): 4365, July 2021.

Reiss KA, Mick R, O'Hara MH, Teitelbaum U, Karasic TB, Schneider C, Cowden S, Southwell T, Romeo J, Isgur N, Hannan ZM, Tondon R, Nathanson K, Vonderheide RH, Wattenberg MM, Beatty G, Domchek SM: Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2. Journal of Clinical Oncology May 2021.

Bear AS, Fraiette JA, Narayan VK, O'Hara M, Haas NB: Adoptive Cellular Therapy for Solid Tumors. American Society for Clinical Oncology Educational Book 41: 57 - 65, March 2021.

O'Hara MH, O'Reilly EM, Varadhachary G, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, Cabanski CR, Mick R, Gherardini PF, Kitch LJ, Xu J, Samuel T, Karakunnel J, Fairchild J, Bucktrout S, LaVallee TM, Selinsky C, Till JE, Carpenter EL, Alanio C, Byrne KT, Chen RO, Trifan OC, Dugan U, Horak C, Hubbard-Lucey VM, Wherry EJ, Ibrahim R, Vonderheide RH: CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncology 22(1): 118 - 131, January 2021.

Patel KK, Stein S, Lacy J, O'Hara M, Huntington SF: Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer. JAMA Network Open January 2021.

Shun, Y. Mamtani R, O'Hara MH, O'Dwyer PJ, Margalit O, Giantonio BJ, Shmueli E, Reiss KA, Boursi B: Comparative Effectiveness of Total Neoadjuvant Therapy Versus Standard Adjuvant Chemotherapy for Locally Advanced Rectal Cancer. Clinical Colorectal Cancer january 2021.

back to top
Last updated: 12/02/2021
The Trustees of the University of Pennsylvania